Advertisement

US buys nearly all available supplies of Remdesivir for next three months

11:06 PM Jul 02, 2020 | Xinhua

U.S. health authorities have said that the country is buying nearly all the global supplies of Remdesivir for COVID-19 treatment for the next three months, which could mean that no other country will be able to buy it in the period.

The U.S. Department of Health and Human Services (HHS) confirmed Monday that it had secured more than 500,000 treatment courses of Remdesivir from the pharmaceutical giant Gilead Sciences -- which is all of the company's production for July and 90 percent of that for August and September -- for U.S. hospitals until September.

Advertisement
Advertisement

A medical worker takes a swab sample at a COVID-19 drive-thru testing site in Washington D.C., the United States, May 19, 2020.

President Donald Trump "has struck an amazing deal to ensure Americans have access to the first authorized therapeutic for COVID-19," HHS Secretary Alex Azar said in a statement on Monday.

Advertisement

Meanwhile, the U.S. move to buy up so much stock of the medicine has drawn criticism from other countries, including its allies, as some others have also participated in trials of Remdesivir, which was developed as a treatment against Ebola but then failed to work as expected.

Since the outbreak of the pandemic, Washington has also invoked the Defense Production Act to block some medical items made in the United States from being exported abroad.

The Remdesivir deal came as the United States saw the pandemic worsening in the country.

Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, prepares to testify before the House Energy and Commerce Committee on Oversight of the Trump Administration's Response to the COVID-19 Pandemic in Washington, D.C., the United States, June 23, 2020. (Sarah Silbiger/Pool via Xinhua)

(To view our epaper please Read Now. For all the latest News, Mumbai, Entertainment, Cricket, Business and Featured News updates, visit Free Press Journal. Also, follow us on Twitter and Instagram and do like our Facebook page for continuous updates on the go)

Advertisement